 |
|
| Global Awards | |
| High grade | High-yield |
| Equity | M&A |
| Structured credit | Restructuring |
| Regional Awards | |
| Asia | Latin America |
| CEE | Middle East |
|
||||||||||||||||||||||||
Take yourself back to the beginning of 2009. A dark cloud hung over the financial markets, the banking system had just been bailed out, yet systemic risk still lingered. The effects of massive central bank stimulus and government-backed bank bond guarantees had yet to kick fully into the sector. Loan markets remained crippled. Beyond the concerns of how companies might refinance their bond maturities, the question was how would any M&A deals be financed? Amid the furore of the crisis, Swiss pharmaceuticals company Roche had engaged in an acquisition play for the remaining 44% of California-based biotechnology company Genentech that it didn’t already own.